SG10201605251VA - Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione - Google Patents
Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dioneInfo
- Publication number
- SG10201605251VA SG10201605251VA SG10201605251VA SG10201605251VA SG10201605251VA SG 10201605251V A SG10201605251V A SG 10201605251VA SG 10201605251V A SG10201605251V A SG 10201605251VA SG 10201605251V A SG10201605251V A SG 10201605251VA SG 10201605251V A SG10201605251V A SG 10201605251VA
- Authority
- SG
- Singapore
- Prior art keywords
- acetylaminoisoindoline
- methanesulfonyl
- dione
- ethoxy
- methoxy
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/403—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil condensed with carbocyclic rings, e.g. carbazole
- A61K31/4035—Isoindoles, e.g. phthalimide
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2013—Organic compounds, e.g. phospholipids, fats
- A61K9/2018—Sugars, or sugar alcohols, e.g. lactose, mannitol; Derivatives thereof, e.g. polysorbates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2004—Excipients; Inactive ingredients
- A61K9/2022—Organic macromolecular compounds
- A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
- A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/282—Organic compounds, e.g. fats
- A61K9/2826—Sugars or sugar alcohols, e.g. sucrose; Derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/2853—Organic macromolecular compounds obtained otherwise than by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyethylene glycol, polyethylene oxide, poloxamers, poly(lactide-co-glycolide)
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P19/00—Drugs for skeletal disorders
- A61P19/06—Antigout agents, e.g. antihyperuricemic or uricosuric agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201161580626P | 2011-12-27 | 2011-12-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201605251VA true SG10201605251VA (en) | 2016-08-30 |
Family
ID=47459206
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201605251VA SG10201605251VA (en) | 2011-12-27 | 2012-12-26 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetylaminoisoindoline-1,3-dione |
SG11201403564YA SG11201403564YA (en) | 2011-12-27 | 2012-12-26 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG11201403564YA SG11201403564YA (en) | 2011-12-27 | 2012-12-26 | Formulations of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione |
Country Status (33)
Country | Link |
---|---|
US (2) | US20130164376A1 (en) |
EP (2) | EP2797581B1 (en) |
JP (1) | JP6161629B2 (en) |
KR (3) | KR20210033073A (en) |
CN (1) | CN104136003A (en) |
AU (1) | AU2012362562B2 (en) |
BR (1) | BR112014015923B1 (en) |
CA (1) | CA2861594A1 (en) |
CL (1) | CL2014001726A1 (en) |
CO (1) | CO7000777A2 (en) |
CR (1) | CR20140314A (en) |
CY (1) | CY1123174T1 (en) |
DK (1) | DK2797581T3 (en) |
EA (1) | EA027801B1 (en) |
EC (1) | ECSP14007965A (en) |
ES (1) | ES2799448T3 (en) |
HK (1) | HK1202056A1 (en) |
HR (1) | HRP20200825T1 (en) |
HU (1) | HUE050327T2 (en) |
IL (1) | IL233296B (en) |
LT (1) | LT2797581T (en) |
MX (2) | MX2014007878A (en) |
NI (1) | NI201400068A (en) |
PE (1) | PE20142318A1 (en) |
PH (1) | PH12014501495B1 (en) |
PL (1) | PL2797581T3 (en) |
PT (1) | PT2797581T (en) |
RS (1) | RS60415B1 (en) |
SG (2) | SG10201605251VA (en) |
SI (1) | SI2797581T1 (en) |
UA (1) | UA113750C2 (en) |
WO (1) | WO2013101810A1 (en) |
ZA (1) | ZA201404629B (en) |
Families Citing this family (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
RU2017121896A (en) | 2011-09-14 | 2019-01-29 | Селджин Корпорейшн | PREPARATIONS {2 - [(1S) -1- (3-Ethoxy-4-methoxyphenyl) -2-methanesulfonylethyl] -3-oxo-2,3-dihydro-1H-isoindole-4-yl} amide cyclopropanecarbonyl |
SI2797581T1 (en) | 2011-12-27 | 2020-08-31 | Amgen (Europe) GmbH | Formulations of (+)-2-(1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl)-4-acetyl aminoisoindoline-1,3-dione |
WO2015173792A1 (en) | 2014-05-11 | 2015-11-19 | Mapi Pharma Ltd. | Amorphous form of apremilast |
EP3174999A1 (en) | 2014-07-29 | 2017-06-07 | Fundació Hospital Universitari Vall d' Hebron - Institut de Recerca | Differential diagnosis and therapy selection for rheumatoid arthritis and psoriatic arthritis |
SI3881833T1 (en) * | 2015-06-30 | 2024-03-29 | Genentech, Inc., | Immediate-release tablets containing a drug and processes for forming the tablets |
CZ20165A3 (en) * | 2016-01-06 | 2017-07-19 | Zentiva, K.S. | A method of preparing amorphous apremilast |
US20190175491A1 (en) | 2016-06-15 | 2019-06-13 | Torrent Pharmaceuticals Limited | Topical compositions of apremilast |
MX2021013317A (en) * | 2019-04-30 | 2022-01-18 | Celgene Corp | Combination therapies comprising apremilast and tyk2 inhibitors. |
ES2823927B2 (en) * | 2019-11-07 | 2022-01-18 | Beijing Enbiwo Biological Tech Co Ltd | Composition in micrometric size and its use as an adjuvant agent of vegetable alkaloids |
KR20220047105A (en) | 2020-10-08 | 2022-04-15 | 주식회사 엔비피헬스케어 | Pharmaceutical composition containing apremilast |
CN112245403B (en) * | 2020-10-23 | 2022-04-22 | 杭州朱养心药业有限公司 | Phosphodiesterase-4 inhibitor and oral solid composition thereof |
EP4183389A1 (en) | 2021-11-18 | 2023-05-24 | KRKA, d.d., Novo mesto | Pharmaceutical composition comprising apremilast |
WO2023118043A1 (en) | 2021-12-22 | 2023-06-29 | Biohorm, S.L. | Pharmaceutical compositions of apremilast |
Family Cites Families (45)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5358941A (en) * | 1992-12-02 | 1994-10-25 | Merck & Co., Inc. | Dry mix formulation for bisphosphonic acids with lactose |
WO1995003009A1 (en) | 1993-07-22 | 1995-02-02 | Oculex Pharmaceuticals, Inc. | Method of treatment of macular degeneration |
WO1995003807A1 (en) | 1993-07-27 | 1995-02-09 | The University Of Sydney | Treatment of age-related macular degeneration |
IT1274549B (en) | 1995-05-23 | 1997-07-17 | Indena Spa | USE OF FLAVANOLIGNANI FOR THE PREPARATION OF MEDICATIONS FOR ANTI-PROLIFERATIVE ACTIVITY IN CANCER OF THE UTERUS, OVARIAN AND BREAST |
US5800819A (en) | 1996-01-25 | 1998-09-01 | National Institute For Pharmaceutical Research And Development Federal Ministry Of Science And Technology | Piper guineense, pterocarpus osun, eugenia caryophyllata, and sorghum bicolor extracts for treating sickle cell disease |
HU228769B1 (en) | 1996-07-24 | 2013-05-28 | Celgene Corp | Substituted 2(2,6-dioxopiperidin-3-yl)phthalimides and -1-oxoisoindolines and their use for production of pharmaceutical compositions for mammals to reduce the level of tnf-alpha |
EP2070920B8 (en) | 1996-07-24 | 2011-04-27 | Celgene Corporation | Substituted 2-(2,6-dioxopiperidin-3-yl)-phthalimides and 1-oxoisoindolines and method of reducing TNF alpha levels |
US6281230B1 (en) | 1996-07-24 | 2001-08-28 | Celgene Corporation | Isoindolines, method of use, and pharmaceutical compositions |
US5635517B1 (en) | 1996-07-24 | 1999-06-29 | Celgene Corp | Method of reducing TNFalpha levels with amino substituted 2-(2,6-dioxopiperidin-3-YL)-1-oxo-and 1,3-dioxoisoindolines |
US6015803A (en) | 1998-05-04 | 2000-01-18 | Wirostko; Emil | Antibiotic treatment of age-related macular degeneration |
US6225348B1 (en) | 1998-08-20 | 2001-05-01 | Alfred W. Paulsen | Method of treating macular degeneration with a prostaglandin derivative |
US6001368A (en) | 1998-09-03 | 1999-12-14 | Protein Technologies International, Inc. | Method for inhibiting or reducing the risk of macular degeneration |
US6020358A (en) * | 1998-10-30 | 2000-02-01 | Celgene Corporation | Substituted phenethylsulfones and method of reducing TNFα levels |
US6448323B1 (en) | 1999-07-09 | 2002-09-10 | Bpsi Holdings, Inc. | Film coatings and film coating compositions based on polyvinyl alcohol |
US7182953B2 (en) | 1999-12-15 | 2007-02-27 | Celgene Corporation | Methods and compositions for the prevention and treatment of atherosclerosis restenosis and related disorders |
CN1511420A (en) | 2001-11-09 | 2004-07-07 | 松下电器产业株式会社 | Moving picture coding method and apparatus |
MY140561A (en) * | 2002-02-20 | 2009-12-31 | Nycomed Gmbh | Dosage form containing pde 4 inhibitor as active ingredient |
US7893101B2 (en) | 2002-03-20 | 2011-02-22 | Celgene Corporation | Solid forms comprising (+)-2-[1-(3-ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione, compositions thereof, and uses thereof |
US6962940B2 (en) * | 2002-03-20 | 2005-11-08 | Celgene Corporation | (+)-2-[1-(3-Ethoxy-4-methoxyphenyl)-2-methylsulfonylethyl]-4-acetylaminoisoindoline-1,3-dione: methods of using and compositions thereof |
US7393862B2 (en) | 2002-05-17 | 2008-07-01 | Celgene Corporation | Method using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for treatment of certain leukemias |
US7968569B2 (en) | 2002-05-17 | 2011-06-28 | Celgene Corporation | Methods for treatment of multiple myeloma using 3-(4-amino-1-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione |
US7323479B2 (en) | 2002-05-17 | 2008-01-29 | Celgene Corporation | Methods for treatment and management of brain cancer using 1-oxo-2-(2,6-dioxopiperidin-3-yl)-4-methylisoindoline |
US7189740B2 (en) | 2002-10-15 | 2007-03-13 | Celgene Corporation | Methods of using 3-(4-amino-oxo-1,3-dihydro-isoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myelodysplastic syndromes |
US20050203142A1 (en) | 2002-10-24 | 2005-09-15 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment, modification and management of pain |
US20040091455A1 (en) | 2002-10-31 | 2004-05-13 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for treatment and management of macular degeneration |
US7563810B2 (en) | 2002-11-06 | 2009-07-21 | Celgene Corporation | Methods of using 3-(4-amino-1-oxo-1,3-dihydroisoindol-2-yl)-piperidine-2,6-dione for the treatment and management of myeloproliferative diseases |
US20050100529A1 (en) | 2003-11-06 | 2005-05-12 | Zeldis Jerome B. | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of asbestos-related diseases and disorders |
CN101966183A (en) | 2003-12-02 | 2011-02-09 | 细胞基因公司 | Methods and compositions for the treatment and management of hemoglobinopathy and anemia |
US20050143344A1 (en) | 2003-12-30 | 2005-06-30 | Zeldis Jerome B. | Methods and compositions using immunomodulatory compounds for the treatment and management of central nervous system disorders or diseases |
EP1737453A4 (en) | 2004-03-22 | 2008-11-26 | Celgene Corp | Methods of using and compositions comprising immunomodulatory compounds for the treatment and management of skin diseases or disorders |
US20050222209A1 (en) | 2004-04-01 | 2005-10-06 | Zeldis Jerome B | Methods and compositions for the treatment, prevention or management of dysfunctional sleep and dysfunctional sleep associated with disease |
JP2007533761A (en) | 2004-04-23 | 2007-11-22 | セルジーン・コーポレーション | Methods of using immunomodulatory compounds and compositions containing immunomodulatory compounds for treating and managing pulmonary hypertension |
WO2006053160A2 (en) | 2004-11-12 | 2006-05-18 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of parasitic diseases |
AU2005309733A1 (en) | 2004-11-23 | 2006-06-01 | Celgene Corporation | Methods and compositions using immunomodulatory compounds for treatment and management of central nervous system injury |
AU2005311888A1 (en) | 2004-12-01 | 2006-06-08 | Celgene Corporation | Compositions comprising immunomodulatory compounds and the use thereof for the treatment of immunodeficiency disorders |
MX2007009812A (en) * | 2005-02-15 | 2007-10-23 | Wyeth Corp | Orally bioavailable cci-779 tablet formulations. |
ES2526415T3 (en) * | 2005-03-17 | 2015-01-12 | Synthon B.V. | Pharmaceutical tablets of crystalline aripiprazole type II |
WO2006111980A2 (en) | 2005-04-20 | 2006-10-26 | Ideal Cures Pvt. Ltd. | Pva based film coating and film coating compositions |
CA2621136C (en) | 2005-09-01 | 2014-10-14 | Celgene Corporation | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
US20070155791A1 (en) * | 2005-12-29 | 2007-07-05 | Zeldis Jerome B | Methods for treating cutaneous lupus using aminoisoindoline compounds |
DE102008047910A1 (en) * | 2008-09-19 | 2010-03-25 | Molkerei Meggle Wasserburg Gmbh & Co. Kg | Tabletting excipient based on lactose and cellulose |
EA201171035A1 (en) | 2009-02-10 | 2012-02-28 | Селджин Корпорейшн | COMPOSITIONS, INCLUDING MODULATORS PDE4, AND METHOD OF THEIR APPLICATION FOR THE TREATMENT, PREVENTION AND SUPPORT OF TUBERCULOSIS |
SI2498759T1 (en) * | 2009-11-13 | 2018-12-31 | Astrazeneca Ab | Immediate release tablet formulations |
EP2651400B2 (en) * | 2010-12-16 | 2023-01-18 | Amgen (Europe) GmbH | Controlled release oral dosage forms of poorly soluble drugs and uses thereof |
SI2797581T1 (en) | 2011-12-27 | 2020-08-31 | Amgen (Europe) GmbH | Formulations of (+)-2-(1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl)-4-acetyl aminoisoindoline-1,3-dione |
-
2012
- 2012-12-26 SI SI201231796T patent/SI2797581T1/en unknown
- 2012-12-26 HU HUE12808662A patent/HUE050327T2/en unknown
- 2012-12-26 US US13/727,366 patent/US20130164376A1/en not_active Abandoned
- 2012-12-26 KR KR1020217008170A patent/KR20210033073A/en not_active IP Right Cessation
- 2012-12-26 PL PL12808662T patent/PL2797581T3/en unknown
- 2012-12-26 JP JP2014550424A patent/JP6161629B2/en active Active
- 2012-12-26 SG SG10201605251VA patent/SG10201605251VA/en unknown
- 2012-12-26 WO PCT/US2012/071623 patent/WO2013101810A1/en active Application Filing
- 2012-12-26 AU AU2012362562A patent/AU2012362562B2/en active Active
- 2012-12-26 CA CA2861594A patent/CA2861594A1/en active Pending
- 2012-12-26 EP EP12808662.6A patent/EP2797581B1/en not_active Revoked
- 2012-12-26 UA UAA201408510A patent/UA113750C2/en unknown
- 2012-12-26 EA EA201491292A patent/EA027801B1/en not_active IP Right Cessation
- 2012-12-26 RS RS20200715A patent/RS60415B1/en unknown
- 2012-12-26 EP EP20172615.5A patent/EP3756650A1/en active Pending
- 2012-12-26 PE PE2014001038A patent/PE20142318A1/en not_active Application Discontinuation
- 2012-12-26 CN CN201280070694.5A patent/CN104136003A/en active Pending
- 2012-12-26 DK DK12808662.6T patent/DK2797581T3/en active
- 2012-12-26 KR KR1020147020953A patent/KR102035362B1/en active IP Right Grant
- 2012-12-26 MX MX2014007878A patent/MX2014007878A/en active IP Right Grant
- 2012-12-26 PT PT128086626T patent/PT2797581T/en unknown
- 2012-12-26 ES ES12808662T patent/ES2799448T3/en active Active
- 2012-12-26 SG SG11201403564YA patent/SG11201403564YA/en unknown
- 2012-12-26 LT LTEP12808662.6T patent/LT2797581T/en unknown
- 2012-12-26 BR BR112014015923-8A patent/BR112014015923B1/en active IP Right Grant
- 2012-12-26 KR KR1020197030218A patent/KR102232154B1/en active IP Right Grant
-
2014
- 2014-06-22 IL IL233296A patent/IL233296B/en active IP Right Grant
- 2014-06-24 ZA ZA2014/04629A patent/ZA201404629B/en unknown
- 2014-06-26 MX MX2020005145A patent/MX2020005145A/en unknown
- 2014-06-26 NI NI201400068A patent/NI201400068A/en unknown
- 2014-06-26 CL CL2014001726A patent/CL2014001726A1/en unknown
- 2014-06-27 CR CR20140314A patent/CR20140314A/en unknown
- 2014-06-27 PH PH12014501495A patent/PH12014501495B1/en unknown
- 2014-07-03 EC ECIEPI20147965A patent/ECSP14007965A/en unknown
- 2014-07-09 CO CO14147911A patent/CO7000777A2/en unknown
-
2015
- 2015-03-12 HK HK15102544.0A patent/HK1202056A1/en unknown
-
2020
- 2020-05-14 US US16/874,424 patent/US20210093573A1/en active Pending
- 2020-05-21 HR HRP20200825TT patent/HRP20200825T1/en unknown
- 2020-06-25 CY CY20201100590T patent/CY1123174T1/en unknown
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HK1202056A1 (en) | Formulations of ()-2-[1-(3-ethoxy-4-methoxy-phenyl)-2- methanesulfonyl-ethyl]-4-acetyl aminoisoindoline-1,3-dione ()-2-[1-(3--4--)-2--]-4- -13- | |
HK1199255A1 (en) | Indazole compounds, compositions and methods of use | |
EP2720631A4 (en) | Surgical alignment using references | |
SG10201605172RA (en) | Compositions and methods for selectively etching titanium nitride | |
ZA201403969B (en) | 2-(substituted-phenyl)=cyclopentane-1,3-dione compounds, and derivatives thereof | |
EP2796109A4 (en) | Dental membrane | |
ZA201402148B (en) | Coolant formulations | |
SI2753311T1 (en) | Antioxidant formulations | |
EP2667868A4 (en) | Bendamustine formulations | |
HRP20190186T1 (en) | New (trimethoxyphenylamino)pyrimidinyl formulations | |
GB201114725D0 (en) | Ophthalmic formulations | |
HK1213785A1 (en) | Oral formulations of angiotensin | |
EP2680774A4 (en) | Fluorescent handpiece | |
GB201110278D0 (en) | Formulations | |
TH1401003680A (en) | Formula of (+)-2-[1-(3-ethoxy-4-methoxy-phenyl)-2-methanesulfonyl-ethyl]-4- aceti L-aminoisoindoline-1,3-dione | |
GB201111578D0 (en) | Pharmeutical formulations | |
GB201107627D0 (en) | Formulations | |
GB201107626D0 (en) | Formulations | |
GB201105410D0 (en) | Formulations | |
GB201105360D0 (en) | Formulations | |
GB201104049D0 (en) | Formulations | |
GB201104048D0 (en) | Formulations | |
GB201102795D0 (en) | Formulations | |
GB201109725D0 (en) | Push-pull outlet |